In cash sav­ing mode, On­corus cuts tri­al, staff, lease, and pipeline

In its third quar­ter re­port, On­corus high­light­ed that it would re­port up­dat­ed Phase I da­ta on its lead can­di­date, an on­colyt­ic virus ther­a­py for sol­id tu­mors, be­fore the end of the year.

Now, that read­out, pushed back to ear­ly 2023, will be the last for ON­CR-177. On­corus an­nounced this morn­ing that it was stop­ping the clin­i­cal tri­al and cut­ting off de­vel­op­ment of the ther­a­py, cast­ing a shad­ow on its un­re­leased re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.